Transition Plan for Medical Devices Issued Emergency Use Authorizations During the Coronavirus Disease 2019 Public Health Emergency; Draft Guidance for Industry and Food and Drug Administration Staff; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request, 72978-72981 [2021-27891]

Download as PDF 72978 Federal Register / Vol. 86, No. 244 / Thursday, December 23, 2021 / Notices 21 CFR part Topic OMB Control No. 807, subpart E ............... 800, 801, and 809 .......... 820 ................................. Premarket notification ............................................................................................................................. Medical Device Labeling Regulations ..................................................................................................... Current Good Manufacturing Practice (CGMP); Quality System (QS) Regulation ................................ 0910–0120 0910–0485 0910–0073 Dated: December 17, 2021. Lauren K. Roth, Associate Commissioner for Policy. Submit either electronic or written comments on the proposed collection of information in the draft guidance by February 22, 2022. ADDRESSES: You may submit comments on any guidance at any time as follows: [FR Doc. 2021–27823 Filed 12–22–21; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2021–D–1149] Transition Plan for Medical Devices Issued Emergency Use Authorizations During the Coronavirus Disease 2019 Public Health Emergency; Draft Guidance for Industry and Food and Drug Administration Staff; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability. The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled ‘‘Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) During the Coronavirus Disease 2019 (COVID–19) Public Health Emergency.’’ FDA recognizes that it will take time for device manufacturers, healthcare facilities, healthcare providers, patients, consumers, and FDA to adjust from policies adopted and operations implemented during the declared public health emergency (PHE) to normal operations. To provide a clear policy for all stakeholders and FDA staff, the Agency is issuing this guidance to describe FDA’s general recommendations for this transition process with respect to devices issued EUAs during the COVID–19 PHE, including recommendations regarding submitting a marketing submission, as applicable, and taking other actions with respect to these devices. This draft guidance is not final nor is it in effect at this time. DATES: Submit either electronic or written comments on the draft guidance by March 23, 2022 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. jspears on DSK121TN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 20:50 Dec 22, 2021 Jkt 256001 Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2021–D–1149 for ‘‘Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) During the Coronavirus Disease 2019 (COVID–19) Public Health Emergency.’’ Received PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 comments will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https:// www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240–402–7500. You may submit comments on any guidance at any time (see 21 CFR 10.115(g)(5)). An electronic copy of the guidance document is available for download from the internet. See the SUPPLEMENTARY INFORMATION section for E:\FR\FM\23DEN1.SGM 23DEN1 Federal Register / Vol. 86, No. 244 / Thursday, December 23, 2021 / Notices jspears on DSK121TN23PROD with NOTICES1 information on electronic access to the guidance. Submit written requests for a single hard copy of the draft guidance document entitled ‘‘Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) During the Coronavirus Disease 2019 (COVID–19) Public Health Emergency’’ to the Office of Policy, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993–0002. Send one selfaddressed adhesive label to assist that office in processing your request. FOR FURTHER INFORMATION CONTACT: With regard to the draft guidance: Joshua Silverstein, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 1615, Silver Spring, MD 20993–0002, 301–796–5155; or Jacqueline Gertz, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 1655, Silver Spring, MD 20993–0002, 240–402–9677. With regard to the proposed collection of information: Amber Sanford, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796– 8867, PRAStaff@fda.hhs.gov. SUPPLEMENTARY INFORMATION: I. Background This draft guidance applies to devices that have been issued EUA under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360bbb–3) on the basis of a devicerelated COVID–19 EUA declaration. This draft guidance does not apply to devices for which FDA has revoked the EUA under section 564(g)(2)(B)–(C) of the FD&C Act because the criteria under section 564(c) of the FD&C Act were no longer met or because other circumstances made such revocation appropriate to protect the public health or safety. FDA is concurrently issuing a companion guidance to describe FDA’s recommendations for transitioning devices that fall within enforcement policies issued during the COVID–19 PHE. Given the magnitude of the COVID–19 PHE, FDA recognizes that some continued flexibility, while still providing necessary oversight, will be appropriate to facilitate an orderly and transparent transition back to normal operations. Further, FDA is taking into account that the manufacture, distribution, and use of devices in the context of the COVID–19 PHE raises unique considerations. These unique VerDate Sep<11>2014 20:50 Dec 22, 2021 Jkt 256001 considerations include, for example, the manufacturing of devices by nontraditional manufacturers to address supply issues and the distribution and use of capital or reusable equipment (e.g., ventilators, extracorporeal membrane oxygenation systems) under an EUA. This draft guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on ‘‘Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) During the Coronavirus Disease 2019 (COVID–19) Public Health Emergency.’’ It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. FDA is concurrently issuing a companion draft guidance to describe FDA’s recommendations for transitioning devices that fall within enforcement policies issued during the COVID–19 PHE. II. Electronic Access Persons interested in obtaining a copy of the draft guidance may do so by downloading an electronic copy from the internet. A search capability for all Center for Devices and Radiological Health guidance documents is available at https://www.fda.gov/medical-devices/ device-advice-comprehensiveregulatory-assistance/guidancedocuments-medical-devices-andradiation-emitting-products. This draft guidance is also available at https:// www.regulations.gov or https:// www.fda.gov/regulatory-information/ search-fda-guidance-documents. Persons unable to download an electronic copy of ‘‘Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) During the COVID–19 Public Health Emergency’’ may send an email request to CDRHGuidance@fda.hhs.gov to receive an electronic copy of the document. Please use the document number 21012 and complete title to identify the draft guidance you are requesting. III. Paperwork Reduction Act of 1995 Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501–3521), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ‘‘Collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 72979 or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) During the Coronavirus Disease 2019 (COVID–19) Public Health Emergency OMB Control Number 0910– 0595; Revision The following paragraphs discuss the one-time burdens associated with information collections found in the draft guidance, ‘‘Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) During the COVID–19 Public Health Emergency.’’ The draft guidance is intended to help facilitate continued patient, consumer, and healthcare provider access to devices needed in the prevention, treatment, and diagnosis of COVID–19. The information collections proposed in the draft guidance would assist the Agency in resource planning for marketing submission review and providing increased support to manufacturers. The information collections also include recommended information to provide in labeling for certain devices to inform potential users of the device’s regulatory status, including physical labeling for lifesupporting/life-sustaining devices. FDA estimates the burden of this collection of information as follows: E:\FR\FM\23DEN1.SGM 23DEN1 72980 Federal Register / Vol. 86, No. 244 / Thursday, December 23, 2021 / Notices TABLE 1—ESTIMATED ONE-TIME BURDEN 1 Number of respondents Activity Total annual responses Average burden per response Total hours Notification of intent ............................................................. Transition plan ..................................................................... Labeling mitigation for reusable devices ............................. Labeling mitigation for devices under FDA review after the EUA termination date ....................................................... 100 340 170 1 1 1 100 340 170 1 2 1.25 100 680 213 340 1 340 1.25 425 Total .............................................................................. ........................ ........................ ........................ ........................ 1,418 1 There jspears on DSK121TN23PROD with NOTICES1 Number of responses per respondent are no capital costs or operating and maintenance costs associated with this collection of information. Notification of intent: In section V.A of the draft guidance, ‘‘ ‘Notifications of Intent’ for Certain Reusable LifeSupporting or Life-Sustaining Devices,’’ FDA recommends that manufacturers of certain life-supporting or life-sustaining devices submit to FDA information regarding whether or not they intend to submit a marketing submission to continue distributing their product after the EUA termination date. The draft guidance recommends that manufacturers of such devices include in this notification: (1) General information (e.g., contact information); (2) the EUA request number; (3) a list of all model numbers or other device identifying information; (4) whether the manufacturer plans to submit a marketing submission; and (5) if not planning to submit a marketing submission, the manufacturer should discuss, as applicable, its plan to stop distribution of the device, to restore the device to a previously FDA-cleared or approved version, to provide a physical copy or electronic updated labeling, and any other efforts to address or mitigate potential risks of devices that remain distributed after the EUA termination date. The manufacturer should submit this information designated with the EUA number as an ‘‘EUA report.’’ FDA recommends that manufacturers notate the following on the cover letter of the submission: ‘‘Attention: Notification of Intent.’’ Based on the current EUA submissions and authorizations, we estimate we will receive 100 notifications of intent for certain lifesupporting or life-sustaining devices. Considering the recommended content of a notification, we estimate that the average burden per response is 1 hour. Transition implementation plan: Section V.B.1 of the draft guidance recommends that manufacturers who intend to continue distribution of their device include with their marketing VerDate Sep<11>2014 20:50 Dec 22, 2021 Jkt 256001 submissions a ‘‘transition implementation plan’’ that addresses the manufacturers’ plans for devices already distributed in the case of a positive decision or a negative decision on its marketing submission. The ‘‘transition implementation plan’’ should include information regarding the estimated number of devices distributed under an EUA currently in U.S. distribution, and a benefit-risk based plan for disposition of distributed product as detailed in the draft guidance. Considering the current EUA submissions and authorizations, the amount of these products that are 510(k) exempt, and the amount of respondents we estimate are likely to pursue marketing submission, we estimate that we will receive transition plans for approximately two-thirds of these products, or about 340 products. Based on the recommended content of a transition plan, we estimate that the average burden per response is 2 hours. Labeling mitigation for reusable devices: The draft guidance indicates that when manufacturers of certain reusable devices do not intend to distribute their device beyond the EUA termination date, FDA does not intend to object to the disposition of already distributed devices (i.e., FDA does not intend to request market removal), as detailed in the draft guidance. The draft guidance states that FDA does not intend to object to reusable, non-life-supporting/non-life-sustaining devices that were distributed before the EUA termination date remaining distributed and being used by their end user. Such devices should either be restored by the manufacturer to the previously FDA-cleared or approved version or have publicly available labeling that accurately describes the product features and regulatory status (i.e., that the product lacks FDA clearance or approval). In addition, the PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 draft guidance recommends that reusable life-supporting/life-sustaining devices (e.g., ventilators, extracorporeal membrane oxygenation systems, continuous renal replacement therapy systems) that were distributed before the EUA termination date remain distributed. Such devices should either be restored by the manufacturer to the previously FDA-cleared or approved version of the device, or have both publicly available and a physical copy of labeling that specifies that the device lacks FDA clearance or approval. We estimate that, on average, updating the labeling will take approximately 1 hour and 15 minutes. We estimate 170 respondents, which is about one-third of devices currently under an EUA issued during the COVID–19 PHE, will make such labeling available. Labeling mitigation for devices under FDA review after the EUA termination date: During the period after the EUA termination date, for devices for which a marketing submission has been accepted by FDA but before FDA has taken final action on the submission, labeling should be updated to accurately state that the product was authorized under an EUA issued during the COVID–19 PHE and remains under FDA review for clearance or approval. We believe updating this labeling will also take approximately 1 hour and 15 minutes per device. We estimate that the majority of devices for which manufacturers pursue a marketing submission may remain under FDA review for clearance or approval during the period after the EUA termination date. This draft guidance also refers to previously approved FDA collections of information. The collections of information in the following FDA regulations and guidance have been approved by OMB as listed in the following table: E:\FR\FM\23DEN1.SGM 23DEN1 Federal Register / Vol. 86, No. 244 / Thursday, December 23, 2021 / Notices 72981 TABLE 2—GUIDANCES AND COLLECTIONS Topic 807, subpart E ............................................................................ 814, subparts A through E .......................................................... 814, subpart H ............................................................................ ‘‘De Novo Classification Process (Evaluation of Automatic Class III Designation)’’. ‘‘Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program’’. 803 .............................................................................................. Premarket notification ................................................................ Premarket approval .................................................................... Humanitarian Device Exemption ............................................... De Novo classification process .................................................. 0910–0120 0910–0231 0910–0332 0910–0844 Q-submissions ........................................................................... 0910–0756 Medical Devices; Medical Device Reporting; Manufacturer reporting, importer reporting, user facility reporting, distributor reporting. Current Good Manufacturing Practice (CGMP); Quality System (QS) Regulation. Electronic Submission of Medical Device Registration and Listing. Corrections and Removals ........................................................ Unique Device Identification ...................................................... Medical Device Labeling ............................................................ Emergency Use Authorization ................................................... 0910–0437 820 .............................................................................................. 807, subparts A through D ......................................................... 806 .............................................................................................. 830 and 801.20 ........................................................................... 800, 801, and 809 ....................................................................... ‘‘Emergency Use Authorization of Medical Products and Related Authorities’’. IV. Other Issues for Consideration As discussed in the draft guidance, FDA understands that it will take time for device manufacturers, healthcare facilities, healthcare providers, patients, consumers, and FDA to adjust from policies adopted and operations implemented during the declared PHE to normal operations. FDA encourages all stakeholders to comment on the following topics: 1. Whether the 180-day period proposed for advance notice of termination of each EUA declaration pertaining to devices would sufficiently allow for an appropriate transition period that avoids exacerbating product shortages and supply chain disruptions. 2. Whether FDA’s issuance of this draft guidance with a proposed transition policy and requesting public comment may help the Agency to satisfy, or otherwise determine how to best satisfy, while also effectively managing Agency resources, the requirement in section 564(b)(2)(B) of the FD&C Act to consult with a manufacturer that was issued an EUA for an unapproved product on the appropriate disposition of the product. Dated: December 20, 2021. Lauren K. Roth, Associate Commissioner for Policy. jspears on DSK121TN23PROD with NOTICES1 OMB Control No. 21 CFR part or guidance [FR Doc. 2021–27891 Filed 12–22–21; 8:45 am] BILLING CODE 4164–01–P VerDate Sep<11>2014 20:50 Dec 22, 2021 Jkt 256001 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2021–D–1128] Digital Health Technologies for Remote Data Acquisition in Clinical Investigations; Draft Guidance for Industry, Investigators, and Other Stakeholders; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice of availability. The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry, investigators, and other stakeholders entitled ‘‘Digital Health Technologies for Remote Data Acquisition in Clinical Investigations.’’ This guidance provides recommendations to sponsors, investigators, and other stakeholders on the use of digital health technologies (DHTs) to acquire data remotely from participants in clinical investigations evaluating medical products. DHTs may take the form of hardware and/or software and may be used to gather health-related information from study participants and transmit that information to study investigators and/ or other authorized parties to evaluate the safety and effectiveness of medical products. DATES: Submit either electronic or written comments on the draft guidance by March 23, 2022 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. SUMMARY: PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 0910–0073 0910–0625 0910–0359 0910–0720 0910–0485 0910–0595 You may submit comments on any guidance at any time as follows: ADDRESSES: Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand Delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management E:\FR\FM\23DEN1.SGM 23DEN1

Agencies

[Federal Register Volume 86, Number 244 (Thursday, December 23, 2021)]
[Notices]
[Pages 72978-72981]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-27891]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2021-D-1149]


Transition Plan for Medical Devices Issued Emergency Use 
Authorizations During the Coronavirus Disease 2019 Public Health 
Emergency; Draft Guidance for Industry and Food and Drug Administration 
Staff; Availability; Agency Information Collection Activities; Proposed 
Collection; Comment Request

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing 
the availability of the draft guidance entitled ``Transition Plan for 
Medical Devices Issued Emergency Use Authorizations (EUAs) During the 
Coronavirus Disease 2019 (COVID-19) Public Health Emergency.'' FDA 
recognizes that it will take time for device manufacturers, healthcare 
facilities, healthcare providers, patients, consumers, and FDA to 
adjust from policies adopted and operations implemented during the 
declared public health emergency (PHE) to normal operations. To provide 
a clear policy for all stakeholders and FDA staff, the Agency is 
issuing this guidance to describe FDA's general recommendations for 
this transition process with respect to devices issued EUAs during the 
COVID-19 PHE, including recommendations regarding submitting a 
marketing submission, as applicable, and taking other actions with 
respect to these devices. This draft guidance is not final nor is it in 
effect at this time.

DATES: Submit either electronic or written comments on the draft 
guidance by March 23, 2022 to ensure that the Agency considers your 
comment on this draft guidance before it begins work on the final 
version of the guidance. Submit either electronic or written comments 
on the proposed collection of information in the draft guidance by 
February 22, 2022.

ADDRESSES: You may submit comments on any guidance at any time as 
follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2021-D-1149 for ``Transition Plan for Medical Devices Issued 
Emergency Use Authorizations (EUAs) During the Coronavirus Disease 2019 
(COVID-19) Public Health Emergency.'' Received comments will be placed 
in the docket and, except for those submitted as ``Confidential 
Submissions,'' publicly viewable at https://www.regulations.gov or at 
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through 
Friday, 240-402-7500.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Dockets Management Staff. If you do not wish 
your name and contact information to be made publicly available, you 
can provide this information on the cover sheet and not in the body of 
your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852, 240-402-7500.
    You may submit comments on any guidance at any time (see 21 CFR 
10.115(g)(5)).
    An electronic copy of the guidance document is available for 
download from the internet. See the SUPPLEMENTARY INFORMATION section 
for

[[Page 72979]]

information on electronic access to the guidance. Submit written 
requests for a single hard copy of the draft guidance document entitled 
``Transition Plan for Medical Devices Issued Emergency Use 
Authorizations (EUAs) During the Coronavirus Disease 2019 (COVID-19) 
Public Health Emergency'' to the Office of Policy, Center for Devices 
and Radiological Health, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993-0002. Send 
one self-addressed adhesive label to assist that office in processing 
your request.

FOR FURTHER INFORMATION CONTACT: 
    With regard to the draft guidance: Joshua Silverstein, Center for 
Devices and Radiological Health, Food and Drug Administration, 10903 
New Hampshire Ave., Bldg. 66, Rm. 1615, Silver Spring, MD 20993-0002, 
301-796-5155; or Jacqueline Gertz, Center for Devices and Radiological 
Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 
66, Rm. 1655, Silver Spring, MD 20993-0002, 240-402-9677.
    With regard to the proposed collection of information: Amber 
Sanford, Office of Operations, Food and Drug Administration, Three 
White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 
20852, 301-796-8867, [email protected].

SUPPLEMENTARY INFORMATION:

I. Background

    This draft guidance applies to devices that have been issued EUA 
under section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C 
Act) (21 U.S.C. 360bbb-3) on the basis of a device-related COVID-19 EUA 
declaration. This draft guidance does not apply to devices for which 
FDA has revoked the EUA under section 564(g)(2)(B)-(C) of the FD&C Act 
because the criteria under section 564(c) of the FD&C Act were no 
longer met or because other circumstances made such revocation 
appropriate to protect the public health or safety. FDA is concurrently 
issuing a companion guidance to describe FDA's recommendations for 
transitioning devices that fall within enforcement policies issued 
during the COVID-19 PHE.
    Given the magnitude of the COVID-19 PHE, FDA recognizes that some 
continued flexibility, while still providing necessary oversight, will 
be appropriate to facilitate an orderly and transparent transition back 
to normal operations. Further, FDA is taking into account that the 
manufacture, distribution, and use of devices in the context of the 
COVID-19 PHE raises unique considerations. These unique considerations 
include, for example, the manufacturing of devices by non-traditional 
manufacturers to address supply issues and the distribution and use of 
capital or reusable equipment (e.g., ventilators, extracorporeal 
membrane oxygenation systems) under an EUA.
    This draft guidance is being issued consistent with FDA's good 
guidance practices regulation (21 CFR 10.115). The draft guidance, when 
finalized, will represent the current thinking of FDA on ``Transition 
Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) 
During the Coronavirus Disease 2019 (COVID-19) Public Health 
Emergency.'' It does not establish any rights for any person and is not 
binding on FDA or the public. You can use an alternative approach if it 
satisfies the requirements of the applicable statutes and regulations.
    FDA is concurrently issuing a companion draft guidance to describe 
FDA's recommendations for transitioning devices that fall within 
enforcement policies issued during the COVID-19 PHE.

II. Electronic Access

    Persons interested in obtaining a copy of the draft guidance may do 
so by downloading an electronic copy from the internet. A search 
capability for all Center for Devices and Radiological Health guidance 
documents is available at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/guidance-documents-medical-devices-and-radiation-emitting-products. This draft guidance is also 
available at https://www.regulations.gov or https://www.fda.gov/regulatory-information/search-fda-guidance-documents. Persons unable to 
download an electronic copy of ``Transition Plan for Medical Devices 
Issued Emergency Use Authorizations (EUAs) During the COVID-19 Public 
Health Emergency'' may send an email request to [email protected] to receive an electronic copy of the document. 
Please use the document number 21012 and complete title to identify the 
draft guidance you are requesting.

III. Paperwork Reduction Act of 1995

    Under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-
3521), Federal Agencies must obtain approval from the Office of 
Management and Budget (OMB) for each collection of information they 
conduct or sponsor. ``Collection of information'' is defined in 44 
U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or 
requirements that members of the public submit reports, keep records, 
or provide information to a third party. Section 3506(c)(2)(A) of the 
PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 
60-day notice in the Federal Register concerning each proposed 
collection of information before submitting the collection to OMB for 
approval. To comply with this requirement, FDA is publishing notice of 
the proposed collection of information set forth in this document.
    With respect to the following collection of information, FDA 
invites comments on these topics: (1) Whether the proposed collection 
of information is necessary for the proper performance of FDA's 
functions, including whether the information will have practical 
utility; (2) the accuracy of FDA's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used; (3) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (4) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques, when 
appropriate, and other forms of information technology.

Transition Plan for Medical Devices Issued Emergency Use Authorizations 
(EUAs) During the Coronavirus Disease 2019 (COVID-19) Public Health 
Emergency OMB Control Number 0910-0595; Revision

    The following paragraphs discuss the one-time burdens associated 
with information collections found in the draft guidance, ``Transition 
Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) 
During the COVID-19 Public Health Emergency.''
    The draft guidance is intended to help facilitate continued 
patient, consumer, and healthcare provider access to devices needed in 
the prevention, treatment, and diagnosis of COVID-19. The information 
collections proposed in the draft guidance would assist the Agency in 
resource planning for marketing submission review and providing 
increased support to manufacturers. The information collections also 
include recommended information to provide in labeling for certain 
devices to inform potential users of the device's regulatory status, 
including physical labeling for life-supporting/life-sustaining 
devices.
    FDA estimates the burden of this collection of information as 
follows:

[[Page 72980]]



                                     Table 1--Estimated One-Time Burden \1\
----------------------------------------------------------------------------------------------------------------
                                                     Number of
            Activity                 Number of     responses per   Total annual   Average burden    Total hours
                                    respondents     respondent       responses     per response
----------------------------------------------------------------------------------------------------------------
Notification of intent..........             100               1             100               1             100
Transition plan.................             340               1             340               2             680
Labeling mitigation for reusable             170               1             170            1.25             213
 devices........................
Labeling mitigation for devices              340               1             340            1.25             425
 under FDA review after the EUA
 termination date...............
                                 -------------------------------------------------------------------------------
    Total.......................  ..............  ..............  ..............  ..............           1,418
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
  information.

    Notification of intent: In section V.A of the draft guidance, `` 
`Notifications of Intent' for Certain Reusable Life-Supporting or Life-
Sustaining Devices,'' FDA recommends that manufacturers of certain 
life-supporting or life-sustaining devices submit to FDA information 
regarding whether or not they intend to submit a marketing submission 
to continue distributing their product after the EUA termination date. 
The draft guidance recommends that manufacturers of such devices 
include in this notification: (1) General information (e.g., contact 
information); (2) the EUA request number; (3) a list of all model 
numbers or other device identifying information; (4) whether the 
manufacturer plans to submit a marketing submission; and (5) if not 
planning to submit a marketing submission, the manufacturer should 
discuss, as applicable, its plan to stop distribution of the device, to 
restore the device to a previously FDA-cleared or approved version, to 
provide a physical copy or electronic updated labeling, and any other 
efforts to address or mitigate potential risks of devices that remain 
distributed after the EUA termination date. The manufacturer should 
submit this information designated with the EUA number as an ``EUA 
report.'' FDA recommends that manufacturers notate the following on the 
cover letter of the submission: ``Attention: Notification of Intent.''
    Based on the current EUA submissions and authorizations, we 
estimate we will receive 100 notifications of intent for certain life-
supporting or life-sustaining devices. Considering the recommended 
content of a notification, we estimate that the average burden per 
response is 1 hour.
    Transition implementation plan: Section V.B.1 of the draft guidance 
recommends that manufacturers who intend to continue distribution of 
their device include with their marketing submissions a ``transition 
implementation plan'' that addresses the manufacturers' plans for 
devices already distributed in the case of a positive decision or a 
negative decision on its marketing submission. The ``transition 
implementation plan'' should include information regarding the 
estimated number of devices distributed under an EUA currently in U.S. 
distribution, and a benefit-risk based plan for disposition of 
distributed product as detailed in the draft guidance.
    Considering the current EUA submissions and authorizations, the 
amount of these products that are 510(k) exempt, and the amount of 
respondents we estimate are likely to pursue marketing submission, we 
estimate that we will receive transition plans for approximately two-
thirds of these products, or about 340 products. Based on the 
recommended content of a transition plan, we estimate that the average 
burden per response is 2 hours.
    Labeling mitigation for reusable devices: The draft guidance 
indicates that when manufacturers of certain reusable devices do not 
intend to distribute their device beyond the EUA termination date, FDA 
does not intend to object to the disposition of already distributed 
devices (i.e., FDA does not intend to request market removal), as 
detailed in the draft guidance.
    The draft guidance states that FDA does not intend to object to 
reusable, non-life-supporting/non-life-sustaining devices that were 
distributed before the EUA termination date remaining distributed and 
being used by their end user. Such devices should either be restored by 
the manufacturer to the previously FDA-cleared or approved version or 
have publicly available labeling that accurately describes the product 
features and regulatory status (i.e., that the product lacks FDA 
clearance or approval). In addition, the draft guidance recommends that 
reusable life-supporting/life-sustaining devices (e.g., ventilators, 
extracorporeal membrane oxygenation systems, continuous renal 
replacement therapy systems) that were distributed before the EUA 
termination date remain distributed. Such devices should either be 
restored by the manufacturer to the previously FDA-cleared or approved 
version of the device, or have both publicly available and a physical 
copy of labeling that specifies that the device lacks FDA clearance or 
approval. We estimate that, on average, updating the labeling will take 
approximately 1 hour and 15 minutes. We estimate 170 respondents, which 
is about one-third of devices currently under an EUA issued during the 
COVID-19 PHE, will make such labeling available.
    Labeling mitigation for devices under FDA review after the EUA 
termination date: During the period after the EUA termination date, for 
devices for which a marketing submission has been accepted by FDA but 
before FDA has taken final action on the submission, labeling should be 
updated to accurately state that the product was authorized under an 
EUA issued during the COVID-19 PHE and remains under FDA review for 
clearance or approval. We believe updating this labeling will also take 
approximately 1 hour and 15 minutes per device. We estimate that the 
majority of devices for which manufacturers pursue a marketing 
submission may remain under FDA review for clearance or approval during 
the period after the EUA termination date.
    This draft guidance also refers to previously approved FDA 
collections of information. The collections of information in the 
following FDA regulations and guidance have been approved by OMB as 
listed in the following table:

[[Page 72981]]



                   Table 2--Guidances and Collections
------------------------------------------------------------------------
                                                            OMB Control
    21 CFR part or guidance               Topic                 No.
------------------------------------------------------------------------
807, subpart E.................  Premarket notification.       0910-0120
814, subparts A through E......  Premarket approval.....       0910-0231
814, subpart H.................  Humanitarian Device           0910-0332
                                  Exemption.
``De Novo Classification         De Novo classification        0910-0844
 Process (Evaluation of           process.
 Automatic Class III
 Designation)''.
``Requests for Feedback and      Q-submissions..........       0910-0756
 Meetings for Medical Device
 Submissions: The Q-Submission
 Program''.
803............................  Medical Devices;              0910-0437
                                  Medical Device
                                  Reporting;
                                  Manufacturer
                                  reporting, importer
                                  reporting, user
                                  facility reporting,
                                  distributor reporting.
820............................  Current Good                  0910-0073
                                  Manufacturing Practice
                                  (CGMP); Quality System
                                  (QS) Regulation.
807, subparts A through D......  Electronic Submission         0910-0625
                                  of Medical Device
                                  Registration and
                                  Listing.
806............................  Corrections and               0910-0359
                                  Removals.
830 and 801.20.................  Unique Device                 0910-0720
                                  Identification.
800, 801, and 809..............  Medical Device Labeling       0910-0485
``Emergency Use Authorization    Emergency Use                 0910-0595
 of Medical Products and          Authorization.
 Related Authorities''.
------------------------------------------------------------------------

IV. Other Issues for Consideration

    As discussed in the draft guidance, FDA understands that it will 
take time for device manufacturers, healthcare facilities, healthcare 
providers, patients, consumers, and FDA to adjust from policies adopted 
and operations implemented during the declared PHE to normal 
operations. FDA encourages all stakeholders to comment on the following 
topics:
    1. Whether the 180-day period proposed for advance notice of 
termination of each EUA declaration pertaining to devices would 
sufficiently allow for an appropriate transition period that avoids 
exacerbating product shortages and supply chain disruptions.
    2. Whether FDA's issuance of this draft guidance with a proposed 
transition policy and requesting public comment may help the Agency to 
satisfy, or otherwise determine how to best satisfy, while also 
effectively managing Agency resources, the requirement in section 
564(b)(2)(B) of the FD&C Act to consult with a manufacturer that was 
issued an EUA for an unapproved product on the appropriate disposition 
of the product.

    Dated: December 20, 2021.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2021-27891 Filed 12-22-21; 8:45 am]
BILLING CODE 4164-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.